An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 546-558

  Sullivan, Sean D ^a,b   Mozaffari, Essy ^a,b   Johnson, Eric S ^a,b   Wolitz, Richard ^c   Follansbee, Stephen E ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VeriTech Corporation   (United States)

^c KAISER PERMANENTE   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CYTOMEGALOVIRUS INFECTION; ECONOMIC ASPECT; FEMALE; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL CARE; NEUTROPENIA; NURSE; ORAL DRUG ADMINISTRATION; PHYSICIAN; REIMBURSEMENT; RETINITIS; SEPSIS; TREATMENT OUTCOME;

EID: 0030011156     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80036-1     Document Type: Article

References (24)

1. Boom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988;109:963-969.
2. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis: Multicenter AIDS cohort study. NEJM. 1993;329: 1922-1926.
3. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis. 1992;166:1223-1227.
4. Buhles WC, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or site-threatening cytomegalovirus infection: Experience in 314 immunocompromised patients. Rev Infect Dis. 1988;10(Suppl 3):S495-S506.
5. Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis. 1988; 158:449-456.
6. Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol. 1992;110:1435-1442.
7. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and AIDS. Arch Ophthalmol. 1989;107:75-80.
8. SOCA Research Group. Foscarnet-ganciclovir CMV retinitis trial-4: Visual outcomes. Ophthalmology. 1994;101:1250-1261.
9. Lee PR, Durbin M, Kahn JG. Cost of HIV and AIDS for privately insured persons in California, 1985-1990. Institute for Health Policy Studies, University of California, San Francisco. Final Report submitted to the Health Resources and Services Administration, US Public Health Service, Contract No. 282-88-0018, September 30, 1991.
10. Hellinger FJ, Fleishman JA, Hsia DC. AIDS treatment costs during the last months of life: Evidence from the ACSUS. Health Serv Res. 1994;29:569-581.
11. Lubitz JD, Prihoda R. The use and costs of Medicare services in the last two years of life. Health Care Financ Rev. 1984;5: 117-131.
12. Pascal A, Jacobson P, Lindsey P, et al. The Effects of the AIDS Epidemic on Traditional Medicaid Populations. Santa Monica, Calif: RAND Corporation; 1992:1-320.
13. Buchanan RJ, Smith SR. Medicaid policies for HIV-related prescription drugs. Health Care Financ Rev. 1994;15:43-62.
14. Drew WL, Ives D, Lalezari JP, et al. A randomized controlled study of the efficacy and safety of oral ganciclovir maintenance treatment of newly diagnosed CMV retinitis in AIDS. NEJM. 1995;333: 615-620.
15. Drummond MF, Davies L. Economic analysis alongside clinical trials. Int J Technol Assess Health Care. 1991;7:561-573.
16. Dalkey NC. The Delphi method: An experimental study of group opinion. Research memorandum RM 58888-PR. Santa Monica, Calif: RAND Corporation; 1969.
17. Mozaffari E, Sullivan SD. Home care reimbursement for intravenous ganciclovir therapy. Am J Health Syst Pharm. 1996; 53:161-163.
18. American Medical Association. Socioeconomic Characteristics of Medical Practice. Chicago: American Medical Association; 1994.
19. Finkler SA. The distinction between costs and charges. Ann Intern Med. 1982;96: 102-122.
20. Price KF. Pricing Medicare's diagnosisrelated groups: Charges versus estimated costs. Health Care Financ Rev. 1989;11: 79-90.
21. Lave JR, Pashos CL, Anderson GF, et al. Costing medical care: Using Medicare administrative data. Med Care. 1994;32: JS77-JS89.
22. van Hout B, Bonsel G, Habbema D, et al. Heart transplantation in the Netherlands: Costs, effects and scenarios. J Health Econ. 1993;12:73-93.
23. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1996;49:95-103.
24. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data: II. When the cost histories are not recorded. Technical Report #139, Department of Biostatistics, University of Washington, Seattle, Washington, 1995.